Alphyn’s Zabalafin Drug Platform is unique, impactful and highly important because it contains multiple bioactive compounds that have multiple mechanisms of action to power a new class of drugs called Multi-Target Therapeutics™. Multi-Target Therapeutic Zabalfin-based drugs are capable of attacking an individual disease in multiple ways and treating multiple different diseases. Zabalafin platform drugs are a highly unique and advantaged in the way they treat disease and in their drug approval process. Alphyn is developing breakthrough therapies to treat the most challenging, severe, and common skin diseases. The first drug candidate, topical Zabalafin Hydrogel, completed two Phase 2a clinical trials in atopic dermatitis (AD), a huge $41 Billion global market. Clinical results better than competitive drugs point to “drug of choice” with an 88 Million global patient population. Alphyn has initiated its Phase 2b global clinical trial in Australia, with first patient already dosed.